Bz. Yang et al., HOW SUBTLE DIFFERENCES IN MHC CLASS-II AFFECT THE SEVERITY OF EXPERIMENTAL MYASTHENIA-GRAVIS, Clinical immunology and immunopathology, 86(1), 1998, pp. 45-58
Myasthenia gravis is an autoimmune disorder characterized by muscle we
akness, due to an antibody-mediated deficit of acetylcholine receptors
(AChRs) at neuromuscular junctions. We analyzed the factors that dete
rmine the severity of experimental myasthenia gravis (EAMG) induced by
immunization with Torpedo AChR, in two congenic strains of mice-He mi
ce, which are highly susceptible to EAMG; and bm12 mice, which are rel
atively resistant, and differ only in a change of three amino acids in
MHC Class II. We prepared large numbers of AChR-specific T cell hybri
domas from each strain and characterized their epitope specificities a
nd T cell receptor (TCR) gene usage: Half the B6 hybridomas responded
to a single AChR peptide (alpha 146-162), and their TCR genes encoded
restricted V alpha and V beta chains and CDR3 motifs. bm12 hybridomas
had different epitope specificities and different, less restricted TCR
genes. APCs were able to present AChR or AChR-derived peptides virtua
lly exclusively to hybridomas of their own strain. Levels of antibodie
s to Torpedo and autoantibodies to mouse AChR were higher in B6 mice,
and were biased toward the IgG2b isotype. We conclude that the ''bette
r fit'' of MHC II, peptide, and TCR in the B6 mice enhanced cognate in
teractions of APCs with T cells, and T cells with B cells, resulting i
n a more abundant and pathogenic AChR antibody response, and thus more
severe EAMG. (C) 1998 Academic Press.